KDR and neoplasm: Clinical evidence that supports vascular normalization includes reduced permeability and reduced tumor-associated edema38, 39 following treatment with the pan-VEGFR inhibiting TKI cediranib in patients with recurrent gliblastoma, as well as reduced interstitial fluid pressure and improved delivery of fluorodeoxyglucose following bevacizumab treatment in rectal carcinoma40.